share_log

Pharmaniaga Turns Quarter Around Recording RM101 Million In Profits

Pharmaniaga Turns Quarter Around Recording RM101 Million In Profits

Pharmaniaga在季度末扭转局面,录得10100万令吉的利润
Business Today ·  2024/11/26 14:39

For the third quarter ended 30 September 2024, Pharmaniaga Berhad recorded RM1,029.8 million in revenue, reflecting a 16.3% increase from RM885.5 million in the corresponding quarter of the previous financial year. This growth was primarily driven by the increased demand in the concession segment, attributed to the addition of new products to the Approved Product Price List and price adjustments.

截至2024年9月30日的第三季度,Pharmaniaga Berhad录得营业收入为RM102980万,较上财年相应季度的RM88550万增长16.3%。这一增长主要得益于特许经营部门需求的增加,这归因于新增产品进入批准产品价格清单和价格调整。

Profit after tax improved significantly from a loss in Q3FY23 to RM101 million in the current quarter.

税后利润显著改善,从Q3FY23的亏损转为当前季度的RM10100万。

The group said the higher revenue was also contributed by increased customer demand in the Indonesia segment, fuelled by a surge in orders from existing principals and additional sales generated from the opening of two new branches in February 2024.

集团表示,营业收入的增加也得益于印度尼西亚部门客户需求的上升,主要是由于现有合作方的订单激增以及2024年2月新开设的两家分店带来的额外销售。

However, this growth was also partially offset by a decline in revenue in the non-concession segment, which was impacted by the completion of the supply of a blood product.
For the period under review, the lower net cash generated from operations was mainly due to the payment of the overdue suppliers. With the higher revenue in the current quarter and the absence of substantial one-off impairments and provisions recorded in the previous corresponding quarter—such as the provision for stock obsolescence of expiring pandemic-related consumables (e.g., personal protective equipment and needles), the write-off of new product development costs due to the non-commercial viability of certain products, and the cessation of non-core businesses, which also led to a write-down of machinery and equipment—the Group's earnings before interest, taxation, depreciation and amortisation (EBITDA) rebounded
significantly to RM166.2 million, compared to a loss before interest, taxation, depreciation and amortisation (LBITDA) of RM30.7 million in the corresponding quarter of the previous year.

然而,这一增长也部分被非特许经营部门营业收入的下降所抵消,该部门受到血制品供应完成的影响。
在审查期间,来自经营活动产生的净现金减少主要是由于对逾期供应商的付款。由于当前季度的营业收入增加且在上一个对应季度没有记录重大的一次性减值和准备,例如过期疫情相关消耗品(如个人防护装备和针头)的存货过时准备、因某些产品未具商业可行性而注销的新产品开发成本,以及非核心业务的终止,也导致了机械和设备的减值,集团的息税折旧摊销前利润(EBITDA)回升
显著回升至RM16620万,相比上年对应季度的息税折旧摊销前亏损(LBITDA)为RM3070万。

Higher payables as of 30 September 2024 were primarily due to increased purchases resulting from the addition of new products to the Approved Product Price List in the new concession period, as well as price revisions under the new concession cycle due to increased supplier costs. Additionally, higher revenue was also contributed by increased customer demand in the Indonesia segment, fueled by a surge in orders from existing principals and additional sales generated from the opening of two new branches in February 2024. However, this growth was partially offset by a decline in revenue in the non-concession segment, which was impacted by the completion of the supply of a blood product.

截至2024年9月30日,应付账款的增加主要是由于因新增产品进入新特许经营期的批准产品价格清单而导致的采购增加,以及由于供应商成本上涨而在新特许经营周期下的价格修订。此外,营业收入的增加也得益于印度尼西亚部门客户需求的上升,主要是由于现有合作方的订单激增以及2024年2月新开设的两家分店带来的额外销售。然而,这一增长被非特许经营部门营业收入的下降部分抵消,该部门受到血制品供应完成的影响。

Correspondingly, the Group's profit before zakat and taxation (PBT) showed a significant improvement to RM138.5 million, compared to a loss before zakat and taxation (LBT) of RM56.3 million in the corresponding quarter of the previous year.

相应地,集团的税前利润(PBT)显著改善至13850万令吉,而去年同期则为5630万令吉的税前亏损(LBT)。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发